BioPharma Resources

Drug Trial Radar · NCT07071623

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 4,580 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,580

Planned (sponsor's estimate)

Start

Nov 10, 2025

Primary completion

Oct 18, 2027

Study completion Oct 18, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it

Conditions

  • Human Immunodeficiency Virus (HIV)
  • HIV Pre-Exposure Prophylaxis

Interventions

  • MK-8527Drug

    Oral tablet

  • Emtricitabine/tenofovir disoproxil (FTC/TDF)Drug

    Oral tablet

  • Placebo matched to MK-8527Drug

    Placebo oral tablet matched to MK-8527

  • Placebo matched to FTC/TDFDrug

    Placebo oral tablet matched to FTC/TDF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) InfectionTime frame: Up to ~2 years
  2. Number of Participants who Experience At Least One Adverse Event (AE)Time frame: Up to ~2 years
  3. Number of Participants who Discontinue Study Intervention Due to an AETime frame: Up to ~2 years

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • Kargeno Research & Policy Hub ( Site 0007)

    Kisumu, Kenya · Recruiting

  • UW - KNH; Rachuonyo County Hospital ( Site 0006)

    Homabay County, Homa Bay County, Kenya · Recruiting

  • Partners in Health and Research Development (PHRD) ( Site 0002)

    Thika, Kiambu County, Kenya · Active not recruiting

  • KEMRI-CMR-RCTP ( Site 0003)

    Nairobi, Kisumu County, Kenya · Recruiting

  • Synergy Biomed Research Institute ( Site 0040)

    East London, Eastern Cape, South Africa · Recruiting

  • Foundation For Professional Development ( Site 0031)

    Ndevana, Eastern Cape, South Africa · Active not recruiting

  • Josha Research ( Site 0045)

    Bloemfontein, Free State, South Africa · Active not recruiting

  • Wits RHI Ward 21 Clinical Research site ( Site 0022)

    Johannesburg, Gauteng, South Africa · Recruiting

  • Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0048)

    Johannesburg, Gauteng, South Africa · Active not recruiting

  • Perinatal HIV Research Unit (PHRU) ( Site 0033)

    Johnnesburg, Gauteng, South Africa · Recruiting

  • Setshaba Research Centre ( Site 0032)

    Pretoria, Gauteng, South Africa · Recruiting

  • SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0026)

    Chatsworth, KwaZulu-Natal, South Africa · Active not recruiting

  • SA Medical Research Council - Botha's Hill Clinical Research Site ( Site 0035)

    Durban, KwaZulu-Natal, South Africa · Active not recruiting

  • CAPRISA eThekwini Clinical Research Site ( Site 0030)

    Durban, KwaZulu-Natal, South Africa · Active not recruiting

  • Wits Maternal Adolescent and Child Health Research Unit (WMRU) ( Site 0027)

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • Umlazi Clinical Research Site ( Site 0047)

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • SYNAPSE Research Clinic ( Site 0043)

    Edendale, KwaZulu-Natal, South Africa · Recruiting

  • Qhakaza Mbokodo Research Clinic ( Site 0028)

    Ladysmith, KwaZulu-Natal, South Africa · Recruiting

  • SA Medical Research Council - Phoenix Clinical Research Site ( Site 0037)

    Phoenix, KwaZulu-Natal, South Africa · Recruiting

  • CAPRISA Vulindlela Clinical Research Site ( Site 0029)

    Pietermaritzburg, KwaZulu-Natal, South Africa · Recruiting

  • Africa Health Research Institute (AHRI) - Mtubatuba ( Site 0049)

    Somkhele - Mtubatuba, KwaZulu-Natal, South Africa · Active not recruiting

  • SA Medical Research Council - Verulam Clinical Research Site ( Site 0036)

    Verulam, KwaZulu-Natal, South Africa · Recruiting

  • Desmond Tutu Health Foundation. Philippi Village ( Site 0024)

    Cape Town, Western Cape, South Africa · Recruiting

  • DTHF Masiphumelele Clinical Research Site ( Site 0023)

    Cape Town, Western Cape, South Africa · Recruiting

  • Vuka Research Clinic ( Site 0025)

    Khayelitsha, Western Cape, South Africa · Active not recruiting

  • MU-JHU Research Collaboration - Kampala ( Site 0062)

    Kampala, Uganda · Recruiting

  • MRC/UVRI and LSHTM Uganda Research Unit Masaka ( Site 0064)

    Entebbe, Central Region, Uganda · Recruiting

  • Infectious Diseases Institute Kalangala ( Site 0063)

    Kalangala District, Kalangala, Uganda · Recruiting

  • MU-JHU Research Collaboration - Mityana ( Site 0061)

    Mityana, District, Mityana, Uganda · Recruiting

  • UVRI Clinical Research Program Initiative Ltd (UVRI CRP) ( Site 0067)

    Entebbe, Wakiso, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.